Nuvation Bio(NUVB.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Nuvation Bio
NUVB.US
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
4.675 T
NUVB.USMarket value -Rank by Market Cap -/-

Financial Score

20/05/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking65/189
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-39.51%E
    • Profit Margin-102.06%E
    • Gross Margin92.80%A
  • Growth ScoreA
    • Revenue YoY1205.52%A
    • Net Profit YoY75.92%A
    • Total Assets YoY23.91%A
    • Net Assets YoY-23.82%E
  • Cash ScoreB
    • Cash Flow Margin86.12%C
    • OCF YoY1205.52%A
  • Operating ScoreD
    • Turnover0.26D
  • Debt ScoreC
    • Gearing Ratio47.63%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer | NUVB Stock News

    StockTitan·
    US
    TMO
    +1.31%
    US
    NUVB
    +0.71%
    US
    IXJ
    +0.79%
    StockTitan·
    US
    TMO
    +1.31%
    US
    NUVB
    +0.71%
    US
    IXJ
    +0.79%

    Nuvation Bio to Participate in Upcoming Investor Conferences

    Unusual Whales·
    US
    NUVB
    +0.71%
    US
    BIB
    +0.05%
    US
    PBE
    +0.11%
    Unusual Whales·
    US
    NUVB
    +0.71%
    US
    BIB
    +0.05%
    US
    PBE
    +0.11%

    Nuvation Bio shares are trading higher after the company reported in-line Q1 EPS results and better-than-expected sales results.

    benzinga_article·
    US
    NUVB
    +0.71%
    US
    XLV
    +1.10%
    US
    FBT
    +0.54%
    benzinga_article·
    US
    NUVB
    +0.71%
    US
    XLV
    +1.10%
    US
    FBT
    +0.54%

    Wedbush Keeps Their Buy Rating on Nuvation Bio (NUVB)

    Tip Ranks·
    US
    NUVB
    +0.71%
    US
    PBE
    +0.11%
    US
    SBIO
    -1.24%
    Tip Ranks·
    US
    NUVB
    +0.71%
    US
    PBE
    +0.11%
    US
    SBIO
    -1.24%

    Nuvation Bio | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 83.23 M

    Earnings Watch·
    US
    NUVB
    +0.71%
    Earnings Watch·
    US
    NUVB
    +0.71%
    © 2026 Longbridge｜Disclaimer